hydralazine and Cardiomegaly
hydralazine has been researched along with Cardiomegaly in 90 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension." | 7.74 | Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. ( Delbosc, S; Jover, B; Mimran, A; Rugale, C, 2007) |
"The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile." | 7.72 | Hydralazine as antihypertensive therapy in obesity-related hypertension. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
" We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)." | 7.70 | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000) |
"The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats." | 7.69 | Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994) |
"The present study was designed to investigate the effect of nicardipine administration upon systolic blood pressure (SBP) and cardiac hypertrophy in spontaneously hypertensive rats (SHR)." | 7.68 | Effect of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study. ( Amenta, F; Bronzetti, E; Ciriaco, E; Felici, L; Ferrante, F, 1992) |
"Evidence of cardiac hypertrophy was slow to resolve despite good control of blood pressure." | 6.64 | Double-blind comparison of minoxidil and hydrallazine in severe hypertension. ( Bennett, CM; Connor, G; Wilburn, RL, 1976) |
"However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd." | 5.43 | Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016) |
"Hydralazine was administered with Ang II infusion (n=10)." | 5.34 | Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II - induced cardiac hypertrophy. ( Ishikawa, K; Kamiyama, Y; Kimura, S; Kobayashi, A; Maruyama, Y; Matsumoto, H, 2007) |
" Since left ventricular hypertrophy may be an important determinant of outcome in hypertension, the long-term effects of arterial vasodilation with hydralazine on left ventricular mass and function were compared with those of an alternative third-line drug, the alpha1 blocker prazosin, in patients still hypertensive despite combined diuretic and beta blocker therapy." | 5.06 | Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. ( Farkas, RM; Leenen, FH; Marquez-Julio, A; Reeves, RA; Smith, DL, 1987) |
" Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension." | 3.76 | HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. ( Cardinale, JP; Elks, CM; Francis, J; Guggilam, A; Mariappan, N; Pariaut, R; Sriramula, S, 2010) |
" Sensitivity of VSCR control of efferent renal sympathetic nerve activity (RSNA) in SHR is restored when cardiac hypertrophy and hypertension are reduced by enalapril treatment." | 3.74 | Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats. ( Abreu, GR; Bissoli, NS; de Andrade, TU; de Melo Cabral, A; Moysés, MR, 2008) |
"The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension." | 3.74 | Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. ( Delbosc, S; Jover, B; Mimran, A; Rugale, C, 2007) |
"Azelnidipine suppressed cardiac hypertrophy, fibrosis, NADPH oxidase and superoxide in spSHRs more potently than amlodipine, and was associated with lower heart rates than amlodipine." | 3.73 | Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. ( Ito, T; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2006) |
"The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile." | 3.72 | Hydralazine as antihypertensive therapy in obesity-related hypertension. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
" Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
"To evaluate the relation of tissue-localized angiotensin II (Ang II) concentration with cardiac hypertrophy and glomerulosclerosis in Tsukuba hypertensive mice (THM) carrying both human renin and angiotensinogen genes." | 3.70 | Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. ( Fukamizu, A; Ishikawa, K; Kai, T; Kurooka, A; Murakami, K; Shimada, S; Sugimura, K; Takenaka, T, 1998) |
"Although evidence has been accumulated to support a role of endothelin-1 (ET-1) in cardiac hypertrophy, details of the pathophysiological significance of ET-1 in cardiac hypertrophy remain to be elucidated." | 3.70 | Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats. ( Adachi, C; Naruse, K; Naruse, M; Seki, T; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T, 2000) |
" We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)." | 3.70 | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000) |
" The role of the renin-angiotensin system (RAS) in cardiac hypertrophy and nephropathy was examined in Tsukuba hypertensive mice (THM) carrying both human renin and angiotensinogen genes." | 3.70 | Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. ( Ishikawa, K; Kai, T; Kurooka, A; Shimada, S; Sugimura, K, 1999) |
"The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats." | 3.69 | Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994) |
"A blunted reduction in total left ventricular load, due to increased pulsatile load in SHR treated with hydralazine, provided a hemodynamic basis for the differential regression of hypertrophy in this model of genetic hypertension." | 3.69 | Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. ( Finn, PV; Mitchell, GF; Pfeffer, JM; Pfeffer, MA, 1996) |
"The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine." | 3.69 | Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension. ( Fukui, T; Horio, T; Kohno, M; Kurihara, N; Takeda, T; Yasunari, K; Yokokawa, K; Yoshiyama, M, 1994) |
"The present study was designed to investigate the effect of nicardipine administration upon systolic blood pressure (SBP) and cardiac hypertrophy in spontaneously hypertensive rats (SHR)." | 3.68 | Effect of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study. ( Amenta, F; Bronzetti, E; Ciriaco, E; Felici, L; Ferrante, F, 1992) |
"To assess a possible involvement of cardiac volume overload in the development of cardiac hypertrophy during chronic arterial vasodilator treatment, changes in indexes of cardiac volume load in relation to changes in cardiac anatomy were evaluated during treatment of normotensive rats with 120 mg/l hydralazine or 120 mg/l minoxidil, with drinking water." | 3.67 | Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats. ( Leenen, FH; Tsoporis, J; Yuan, BX, 1989) |
"To determine if a remodeling of the collagen matrix would occur in the absence of hypertrophy and cell necrosis and if such a remodeling could alter active and passive stiffness of the intact myocardium, five rats with genetic hypertension (SHR) were treated (SHRT) with hydralazine for 32 weeks, beginning at four weeks of age, and compared to six age- and sex-matched SHR and seven Wistar-Kyoto genetic control rats (WKY)." | 3.67 | Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats. ( Janicki, JS; Narayan, S; Pick, R; Shroff, SG; Weber, KT, 1989) |
"To investigate the relationship between cardiac hypertrophy associated with hypertension, and the alterations in myocardial lipid metabolism, nicardipine (160 mg/kg/day), hydralazine (40 mg/kg/day), and enalapril (30 mg/kg/day) were administered to spontaneously hypertensive rats from 20 to 24 weeks of age." | 3.67 | Fatty acid binding protein of cardiac muscle in spontaneously hypertensive rats: effect of hypertrophy and its regression. ( Fujii, S; Kawaguchi, H; Okamoto, H; Saito, H; Togashi, H; Yasuda, H, 1988) |
" In order to study the relative roles of hypertension and cardiac hypertrophy in the depression of SHR function, 20-week old SHRs and normotensive rats were treated for 10 weeks with either hydralazine (100 mg X litre-1) or alpha-methyldopa (8 g X litre-1)." | 3.66 | Effect of antihypertensive therapy on calcium transport by cardiac sarcoplasmic reticulum of SHRs. ( Limas, CJ; Spier, SS, 1980) |
"Ventricular arrhythmia was a significant independent predictor in V-HeFT II but not in V-HeFT I." | 2.67 | Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Fletcher, R; Johnson, GR; Loeb, H; Rector, T; Shabetai, R; Smith, R; Tristani, F, 1993) |
"Evidence of cardiac hypertrophy was slow to resolve despite good control of blood pressure." | 2.64 | Double-blind comparison of minoxidil and hydrallazine in severe hypertension. ( Bennett, CM; Connor, G; Wilburn, RL, 1976) |
"However, it is generally accepted that cardiac hypertrophy is one of the most critical risk factors of heart disease." | 2.40 | Role of the renin-angiotensin system in cardiac hypertrophy. ( Komuro, I; Yamazaki, T; Yazaki, Y, 1999) |
"However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd." | 1.43 | Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016) |
"Hydralazine did not affect cardiac hypertrophy in wild-type mice and mice lacking either AT(1) or AT(2) receptors alone." | 1.36 | Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. ( Harada, M; Horiuchi, M; Kishimoto, I; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Rong, X; Saito, Y, 2010) |
"Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4." | 1.36 | Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. ( Hatipoglu, FO; Hirohata, S; Iwamoto, M; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Ohtsuki, T; Shinohata, R; Yamamoto, K, 2010) |
"Hydralazine was administered with Ang II infusion (n=10)." | 1.34 | Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II - induced cardiac hypertrophy. ( Ishikawa, K; Kamiyama, Y; Kimura, S; Kobayashi, A; Maruyama, Y; Matsumoto, H, 2007) |
"Our data suggest that 1) cardiac hypertrophy in SHRs is partly due to NF-kappaB activation, 2) inhibition of NF-kappaB activity by PDTC parallels regression of hypertrophy, and 3) regression of hypertrophy is partly due to inhibition of NF-kappaB activity, independent of hypertension." | 1.33 | Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. ( Gupta, S; Sen, S; Young, D, 2005) |
"Cardiac hypertrophy was reduced by all three treatments, but to a lesser extent by hydralazine (treatment study), and this regression of cardiac hypertrophy persisted only with both types of RAS inhibition (withdrawal study)." | 1.31 | Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. ( Paull, JR; Widdop, RE, 2001) |
"Regression of cardiac hypertrophy was accompanied by a 50% to 300% increase in DNA fragmentation and a >20% reduction in DNA synthesis, resulting in a >20% reduction in cardiac DNA content after 4 weeks." | 1.30 | Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. ( Dam, TV; deBlois, D; Hamet, P; Moreau, P; Tea, BS, 1999) |
"Cardiac hypertrophy was shown to be related to age and gender with the copy number of mouse renin transgenes having an additive effect." | 1.30 | Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27. ( Brosnan, MJ; Clark, JS; Devlin, AM; Dominiczak, AF; Mullins, JJ, 1999) |
"Cardiac hypertrophy was assessed by the left ventricle plus septum weight to body weight ratio and vascular hypertrophy by flow-cytometry analysis of vascular smooth muscle cell polyploidy." | 1.30 | Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. ( Anderson, NH; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; Morton, JJ; Reid, JL; Schork, NJ, 1999) |
"Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis." | 1.29 | Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. ( Egashira, K; Kadokami, T; Numaguchi, K; Shimokawa, H; Sueishi, K; Takemoto, M; Takeshita, A, 1995) |
"Treatment with hydralazine decreased blood pressure in a similar way as trandolapril but did not affect either LV weight or LV Ang II." | 1.28 | Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. ( Higaki, J; Higashimori, K; Mikami, H; Nagano, M; Nagano, N; Nakamura, F; Ogihara, T, 1992) |
"Captopril was less effective in improving maximal coronary blood flow but was as effective as cilazapril in reducing cardiac hypertrophy." | 1.28 | Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. ( Clozel, JP; Hess, P; Sprecher, U; Véniant, M, 1991) |
"Hydralazine treatment normalized blood pressure in SHR but did not cause regression of cardiac hypertrophy (heart weight to body weight ratio of SHR + hydralazine 4." | 1.28 | Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. ( Anderson, PG; Bishop, SP; Digerness, SB, 1989) |
"Hydralazine tended to lower LV MCVR per 100 g in both strains despite its tendency to increase ventricular mass." | 1.28 | Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. ( Canby, CA; Tomanek, RJ, 1989) |
"Treatment with hydralazine did not affect left ventricular weight and caused a small increase in the weight of the right ventricle." | 1.27 | Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. ( Leenen, FH; Tsoporis, J, 1988) |
"Even though cardiac hypertrophy is viewed as a beneficial compensatory process that normalizes wall stress, the increased muscle mass carries with it the need of increased blood supply." | 1.27 | Effects of vasodilators on the coronary circulation in congestive heart failure. ( Burkart, F; Kiowski, W, 1988) |
"Hydralazine treatment prevented hypertension in DOCA + HYD but did not prevent development of cardiac hypertrophy (heart weight/body weight of DOCA + HYD 3." | 1.27 | Coronary vascular function and morphology in hydralazine treated DOCA salt rats. ( Anderson, PG; Bishop, SP; Digerness, SB, 1988) |
"Prehydralazine baseline data were therefore compared with values 35 minutes after hydralazine." | 1.26 | Hemodynamic effects of hydralazine in infants with a large ventricular septal defect. ( Beekman, RH; Rocchini, AP; Rosenthal, A, 1982) |
Research
Studies (90)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 35 (38.89) | 18.7374 |
1990's | 25 (27.78) | 18.2507 |
2000's | 23 (25.56) | 29.6817 |
2010's | 7 (7.78) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Thandapilly, SJ | 1 |
Louis, XL | 1 |
Behbahani, J | 1 |
Movahed, A | 1 |
Yu, L | 1 |
Fandrich, R | 1 |
Zhang, S | 1 |
Kardami, E | 1 |
Anderson, HD | 1 |
Netticadan, T | 1 |
Katayama, IA | 2 |
Pereira, RC | 1 |
Dopona, EP | 1 |
Shimizu, MH | 1 |
Furukawa, LN | 2 |
Oliveira, IB | 2 |
Heimann, JC | 2 |
Tanno, T | 1 |
Tomita, H | 1 |
Narita, I | 1 |
Kinjo, T | 1 |
Nishizaki, K | 1 |
Ichikawa, H | 1 |
Kimura, Y | 1 |
Tanaka, M | 1 |
Osanai, T | 1 |
Okumura, K | 1 |
de Andrade, TU | 1 |
Abreu, GR | 1 |
Moysés, MR | 1 |
de Melo Cabral, A | 1 |
Bissoli, NS | 1 |
Siedlecki, AM | 1 |
Jin, X | 1 |
Muslin, AJ | 1 |
Kawamura, M | 1 |
Itoh, H | 1 |
Yura, S | 1 |
Mogami, H | 1 |
Fujii, T | 1 |
Kanayama, N | 1 |
Konishi, I | 1 |
Li, Y | 1 |
Saito, Y | 1 |
Kuwahara, K | 1 |
Rong, X | 1 |
Kishimoto, I | 1 |
Harada, M | 1 |
Horiuchi, M | 1 |
Murray, M | 1 |
Nakao, K | 1 |
Cardinale, JP | 1 |
Sriramula, S | 1 |
Pariaut, R | 1 |
Guggilam, A | 1 |
Mariappan, N | 1 |
Elks, CM | 1 |
Francis, J | 1 |
Ferreira, DN | 1 |
Rosa, KT | 1 |
Coelho, MS | 1 |
Casarini, DE | 1 |
Iwamoto, M | 1 |
Hirohata, S | 1 |
Ogawa, H | 2 |
Ohtsuki, T | 1 |
Shinohata, R | 1 |
Miyoshi, T | 1 |
Hatipoglu, FO | 1 |
Kusachi, S | 1 |
Yamamoto, K | 1 |
Ninomiya, Y | 1 |
Sanada, S | 2 |
Node, K | 2 |
Asanuma, H | 3 |
Ogita, H | 2 |
Takashima, S | 3 |
Minamino, T | 4 |
Asakura, M | 2 |
Liao, Y | 1 |
Ogai, A | 2 |
Kim, J | 2 |
Hori, M | 3 |
Kitakaze, M | 4 |
Carroll, JF | 1 |
King, JW | 1 |
Cohen, JS | 1 |
Gupta, S | 1 |
Young, D | 1 |
Sen, S | 4 |
Okazaki, H | 1 |
Tsukamoto, O | 1 |
Okada, K | 1 |
Myoishi, M | 1 |
Wakeno, M | 1 |
Mochizuki, N | 1 |
Liang, Q | 1 |
Elson, AC | 1 |
Gerdes, AM | 1 |
Yamamoto, E | 1 |
Lai, ZF | 1 |
Yamashita, T | 1 |
Tanaka, T | 1 |
Kataoka, K | 1 |
Tokutomi, Y | 1 |
Ito, T | 1 |
Kim-Mitsuyama, S | 1 |
Baumann, M | 1 |
Janssen, BJ | 1 |
Hermans, JJ | 1 |
Peutz-Kootstra, C | 1 |
Witzke, O | 1 |
Smits, JF | 2 |
Struijker Boudier, HA | 1 |
Vellaichamy, E | 1 |
Zhao, D | 1 |
Somanna, N | 1 |
Pandey, KN | 1 |
Shi, YX | 1 |
Chen, Y | 1 |
Zhu, YZ | 1 |
Huang, GY | 1 |
Moore, PK | 1 |
Huang, SH | 1 |
Yao, T | 1 |
Zhu, YC | 1 |
Rugale, C | 1 |
Delbosc, S | 1 |
Mimran, A | 1 |
Jover, B | 1 |
Kobayashi, A | 1 |
Ishikawa, K | 4 |
Matsumoto, H | 1 |
Kimura, S | 1 |
Kamiyama, Y | 1 |
Maruyama, Y | 1 |
Menard, J | 1 |
Michel, JB | 1 |
Dussaule, JC | 1 |
Alhenc-Gelas, F | 1 |
Corvol, P | 1 |
Artese, D | 1 |
Albani, A | 1 |
Di Tomasso, E | 1 |
Hilliker, KS | 1 |
Roth, RA | 1 |
Bing, OH | 1 |
Conrad, CH | 1 |
Brooks, WW | 1 |
Tarazi, RC | 2 |
Greenberg, BH | 1 |
Rahimtoola, SH | 1 |
Bolte, HD | 1 |
Limas, CJ | 1 |
Spier, SS | 1 |
Beekman, RH | 1 |
Rocchini, AP | 1 |
Rosenthal, A | 1 |
Pegram, BL | 1 |
Ishise, S | 1 |
Frohlich, ED | 1 |
Numaguchi, K | 1 |
Egashira, K | 1 |
Takemoto, M | 1 |
Kadokami, T | 1 |
Shimokawa, H | 1 |
Sueishi, K | 1 |
Takeshita, A | 1 |
Golomb, E | 1 |
Abassi, ZA | 1 |
Cuda, G | 1 |
Stylianou, M | 1 |
Panchal, VR | 1 |
Trachewsky, D | 1 |
Keiser, HR | 1 |
Benetos, A | 1 |
Albaladejo, P | 1 |
Levy, BI | 1 |
Safar, ME | 1 |
Kohno, M | 2 |
Fukui, T | 1 |
Horio, T | 2 |
Yokokawa, K | 2 |
Yasunari, K | 2 |
Yoshiyama, M | 1 |
Kurihara, N | 2 |
Takeda, T | 2 |
Cohn, JN | 1 |
Johnson, GR | 1 |
Shabetai, R | 1 |
Loeb, H | 1 |
Tristani, F | 1 |
Rector, T | 1 |
Smith, R | 1 |
Fletcher, R | 1 |
Reddy, DS | 1 |
Singh, M | 1 |
Ganguly, NK | 1 |
Mitchell, GF | 1 |
Pfeffer, MA | 1 |
Finn, PV | 1 |
Pfeffer, JM | 1 |
Zolk, O | 1 |
Flesch, M | 1 |
Schnabel, P | 1 |
Teisman, AC | 1 |
Pinto, YM | 1 |
van Gilst, WH | 1 |
Paul, M | 1 |
Böhm, M | 1 |
Kai, T | 3 |
Kino, H | 1 |
Shimada, S | 2 |
Sugimura, K | 2 |
Kurooka, A | 2 |
Takenaka, T | 1 |
Fukamizu, A | 1 |
Murakami, K | 1 |
Anderson, NH | 1 |
Devlin, AM | 2 |
Graham, D | 1 |
Morton, JJ | 1 |
Hamilton, CA | 1 |
Reid, JL | 1 |
Schork, NJ | 1 |
Dominiczak, AF | 2 |
Brosnan, MJ | 1 |
Clark, JS | 1 |
Mullins, JJ | 1 |
Tea, BS | 1 |
Dam, TV | 1 |
Moreau, P | 1 |
Hamet, P | 1 |
deBlois, D | 1 |
Kim, L | 1 |
Lee, T | 1 |
Fu, J | 1 |
Ritchie, ME | 1 |
Kawano, H | 1 |
Cody, RJ | 1 |
Graf, K | 1 |
Goetze, S | 1 |
Kawano, Y | 1 |
Schnee, J | 1 |
Law, RE | 1 |
Hsueh, WA | 1 |
Mervaala, E | 1 |
Müller, DN | 2 |
Schmidt, F | 2 |
Park, JK | 2 |
Gross, V | 1 |
Bader, M | 1 |
Breu, V | 2 |
Ganten, D | 2 |
Haller, H | 2 |
Luft, FC | 2 |
Yamazaki, T | 1 |
Komuro, I | 1 |
Yazaki, Y | 1 |
Mervaala, EM | 1 |
Dechend, R | 1 |
Genersch, E | 1 |
Löffler, BM | 1 |
Schneider, W | 1 |
Tanabe, A | 1 |
Naruse, M | 1 |
Adachi, C | 1 |
Seki, T | 1 |
Yoshimoto, T | 1 |
Takagi, S | 1 |
Naruse, K | 1 |
Takano, K | 1 |
Papst, PJ | 1 |
Ueda, Y | 1 |
Sakata, Y | 1 |
Kuzuya, T | 1 |
Terada, N | 1 |
Nakaya, H | 1 |
Sasamura, H | 1 |
Hayashi, M | 1 |
Saruta, T | 1 |
Knowles, JW | 1 |
Esposito, G | 1 |
Mao, L | 1 |
Hagaman, JR | 1 |
Fox, JE | 1 |
Smithies, O | 1 |
Rockman, HA | 1 |
Maeda, N | 1 |
Paull, JR | 1 |
Widdop, RE | 1 |
Connor, G | 1 |
Wilburn, RL | 1 |
Bennett, CM | 1 |
Manegold, C | 1 |
Patzschke, U | 1 |
Markenson, JA | 1 |
Sherman, RL | 1 |
Yamada, T | 1 |
Kubota, T | 1 |
Endo, T | 1 |
Komatus, H | 1 |
Oba, M | 1 |
Nagata, H | 1 |
Izumiyama, T | 1 |
Lloyd, EA | 1 |
Ferrante, F | 1 |
Bronzetti, E | 1 |
Ciriaco, E | 1 |
Felici, L | 1 |
Amenta, F | 1 |
Yuan, B | 1 |
Leenen, FH | 6 |
Nagano, M | 1 |
Higaki, J | 1 |
Nakamura, F | 1 |
Higashimori, K | 1 |
Nagano, N | 1 |
Mikami, H | 1 |
Ogihara, T | 1 |
Cleutjens, JP | 1 |
van Krimpen, C | 1 |
Schoemaker, RG | 1 |
Daemen, MJ | 1 |
Clozel, JP | 1 |
Véniant, M | 1 |
Hess, P | 1 |
Sprecher, U | 1 |
Matsubara, H | 1 |
Yamamoto, J | 1 |
Hirata, Y | 1 |
Mori, Y | 1 |
Oikawa, S | 1 |
Inada, M | 1 |
Canby, CA | 2 |
Tomanek, RJ | 2 |
Murakawa, K | 1 |
Strauer, BE | 1 |
Tsoporis, J | 3 |
Yuan, BX | 1 |
Vial, JH | 1 |
Yong, AC | 1 |
Boyd, GW | 1 |
Nielsen, H | 1 |
Christensen, HR | 1 |
Christensen, KL | 1 |
Baandrup, U | 1 |
Jespersen, LT | 1 |
Anderson, PG | 2 |
Bishop, SP | 2 |
Digerness, SB | 2 |
Narayan, S | 1 |
Janicki, JS | 1 |
Shroff, SG | 1 |
Pick, R | 1 |
Weber, KT | 1 |
Bedotto, JB | 1 |
Gay, RG | 1 |
Graham, SD | 1 |
Morkin, E | 1 |
Goldman, S | 1 |
Fujii, S | 1 |
Kawaguchi, H | 1 |
Okamoto, H | 1 |
Saito, H | 1 |
Togashi, H | 1 |
Yasuda, H | 1 |
Rambausek, M | 1 |
Ritz, E | 1 |
Mall, G | 1 |
Mehls, O | 1 |
Katus, H | 1 |
Smith, DL | 1 |
Farkas, RM | 1 |
Reeves, RA | 1 |
Marquez-Julio, A | 1 |
Kiowski, W | 1 |
Burkart, F | 1 |
Lalich, JJ | 1 |
Paik, WC | 1 |
Poblete, PF | 1 |
Kyle, MC | 1 |
Pipberger, HV | 1 |
Freis, ED | 1 |
Weiss, L | 1 |
Khairallah, PA | 1 |
Bumpus, FM | 1 |
Kilcoyne, MM | 1 |
Thomson, GE | 1 |
Branche, G | 1 |
Williams, M | 1 |
Garnier, C | 1 |
Chiles, B | 1 |
Soland, T | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
[NCT00005122] | 0 participants | Observational | 1958-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
4 reviews available for hydralazine and Cardiomegaly
Article | Year |
---|---|
[Treatment of heart failure with vasodilators].
Topics: Captopril; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Heart Failure; Heart Function Tests; | 1980 |
Role of the renin-angiotensin system in cardiac hypertrophy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Cardiac remodeling in hypertension and following myocardial infarction: effects of arteriolar vasodilators.
Topics: Animals; Arterioles; Cardiomegaly; Extracellular Matrix; Humans; Hydralazine; Hypertension; Myocardi | 1991 |
Trials
4 trials available for hydralazine and Cardiomegaly
Article | Year |
---|---|
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Arrhythmias, Cardiac; Cardiomegaly; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hyd | 1993 |
Double-blind comparison of minoxidil and hydrallazine in severe hypertension.
Topics: Adult; Aged; Cardiomegaly; Creatinine; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged; | 1976 |
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
Topics: Adult; Cardiomegaly; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged; Prazosin; Vasodil | 1987 |
Effect of treatment on morbidity in hypertension. Veterans Administration Cooperative Study on Antihypertensive Agents. Effect on the electrocardiogram.
Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiomegaly; Clinical Trials as Topi | 1973 |
Other Studies
82 other studies available for hydralazine and Cardiomegaly
Article | Year |
---|---|
Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cardiovascular System; Disease Model | 2013 |
High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
Topics: Acetylcysteine; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body | 2014 |
Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression.
Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Imidazoles; Male; Mic | 2016 |
Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Baroreflex; Body Weight; Cardiomegaly; Enalapril; Heart; Hemodynam | 2008 |
Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure.
Topics: Animals; Blood Pressure; Cardiomegaly; Cardiomyopathy, Hypertrophic; Carrier Proteins; Extracellular | 2009 |
Angiotensin II receptor blocker candesartan cilexetil, but not hydralazine hydrochloride, protects against mouse cardiac enlargement resulting from undernutrition in utero.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caloric Restriction; Cardiomegaly; Disease Models, Anim | 2009 |
Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.
Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Male; Mice; Mice, Inb | 2010 |
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Echocardiography; Histone Deacetylas | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Car | 2010 |
Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Body Weight; Cardiomegaly; Glyburide; Hydralazine; | 2002 |
[Opening of ATP-sensitive potassium channel attenuates cardiac remodeling induced by chronic inhibition of nitric oxide synthesis].
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Cardiomegaly; Chromans; Hydralazine; Mitogen-Activa | 2003 |
Hydralazine as antihypertensive therapy in obesity-related hypertension.
Topics: Animals; Antihypertensive Agents; Biometry; Blood Pressure; Cardiomegaly; Female; Heart Rate; Hormon | 2004 |
Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Disease | 2005 |
Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2006 |
p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Female; Heart Failure; Hydralazine; | 2006 |
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Cardiomegaly; Dihydropyridines; Endomyocardial Fibros | 2006 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy.
Topics: Angiotensin II; Animals; Captopril; Cardiomegaly; Cyclic GMP; Fibrosis; Gene Expression Regulation; | 2007 |
Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Cardiomegaly; Cardiotonic | 2007 |
Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Topics: Acetophenones; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Cardiome | 2007 |
Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II - induced cardiac hypertrophy.
Topics: Angiotensin II; Animals; Antioxidants; Aorta; Blood Pressure; Carbon Monoxide; Carboxyhemoglobin; Ca | 2007 |
Potentials and limitations of angiotensin converting enzyme inhibition in the treatment of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Clonidine; | 1984 |
[Vasodilator drugs in the therapy of chronic congestive heart failure. Clinico-case contribution].
Topics: Blood Pressure; Cardiomegaly; Chronic Disease; Drug Evaluation; Heart; Heart Failure; Humans; Hydral | 1983 |
Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
Topics: Animals; Body Weight; Cardiomegaly; Dexamethasone; Heart Diseases; Hydralazine; L-Lactate Dehydrogen | 1984 |
Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment.
Topics: Animals; Body Weight; Cardiomegaly; Collagen; Guanethidine; Heart Failure; Hydralazine; Hypertension | 1984 |
Regression of myocardial hypertrophy and influence of adrenergic system.
Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Dose-Response Relationship, Drug; Hydralazine | 1983 |
Long-term vasodilator therapy in aortic insufficiency. Evidence for regression of left ventricular dilatation and hypertrophy and improvement in systolic pump function.
Topics: Aortic Valve Insufficiency; Cardiac Catheterization; Cardiomegaly; Female; Humans; Hydralazine; Midd | 1980 |
Effect of antihypertensive therapy on calcium transport by cardiac sarcoplasmic reticulum of SHRs.
Topics: Adenosine Triphosphatases; Animals; Biological Transport; Calcium; Cardiomegaly; Hydralazine; Hypert | 1980 |
Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
Topics: Blood Pressure; Cardiomegaly; Female; Heart Failure; Heart Septal Defects, Ventricular; Hemodynamics | 1982 |
Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats.
Topics: Animals; Cardiomegaly; Clonidine; Heart; Hemodynamics; Hydralazine; Hypertension; Methyldopa; Organ | 1982 |
Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats.
Topics: Animals; Arginine; Blood Pressure; Cardiomegaly; Coronary Circulation; Coronary Vessels; Data Interp | 1995 |
Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats.
Topics: Actins; Angiotensin II; Animals; Base Sequence; Biphenyl Compounds; Blood Pressure; Captopril; Cardi | 1994 |
Acute and long-term effects of angiotensin converting enzyme inhibition on larger arteries and cardiac hypertrophy: mechanical and structural parameters.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Blood Pressure; Cardiomegaly; Complianc | 1994 |
Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension.
Topics: Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiom | 1994 |
Effects of long-term hydralazine treatment on myocardial structure and expression of myosin isogenes in cardiac pressure overload in rats.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Models | 1996 |
Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Captopril; Cardiomegaly; Hemodynamics; Hydralazine; Hypertension; | 1996 |
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
Topics: Adenylyl Cyclases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anima | 1998 |
Role of the renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in transgenic hypertensive mice carrying both human renin and angiotensinogen genes.
Topics: Albuminuria; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Drinking; Fibronectins; Gene Ex | 1998 |
Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cat | 1998 |
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Cell Nucleus; Diastole; DNA; | 1999 |
Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice.
Topics: Angiotensin II; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Humans; Hydralazine; Hyperte | 1999 |
Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive A | 1999 |
Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 1999 |
Characterization of MAP kinase and PKC isoform and effect of ACE inhibition in hypertrophy in vivo.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Enzyme Act | 1999 |
Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
Topics: Actinin; Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antigens, CD; Antih | 2000 |
Blood pressure-independent effects in rats with human renin and angiotensinogen genes.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi | 2000 |
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi | 2000 |
Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Endothelin-1; Hydralazi | 2000 |
Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy associated with the activation of p70 S6 kinase in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Coronary Vessels; D | 2000 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Enalapril; Furosemide; Guanylate Cyc | 2001 |
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2001 |
[Regression of left ventricular hypertophy in the ECG during antihypertensive treatment: preliminary observations (author's transl)].
Topics: Adult; Aged; Cardiomegaly; Chlorthalidone; Electrocardiography; Female; Humans; Hydralazine; Hyperte | 1979 |
Renal involvement in progressive systemic sclerosis: prolonged survival with aggressive antihypertensive management.
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Digoxin; Drug Therapy, Combination; Female; Furosemide | 1979 |
Effects of antihypertensive treatment on left ventricular hypertrophy in patients with essential hypertension.
Topics: Adult; Aged; Animals; Antihypertensive Agents; Cardiomegaly; Electrocardiography; Female; Heart Vent | 1979 |
Effect of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study.
Topics: Animals; Cardiomegaly; Drug Evaluation, Preclinical; Hydralazine; Hypertension; Male; Microscopy, El | 1992 |
Chronic arterial vasodilation, central hemodynamics, and cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Arteries; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Drinking; Heart Rate; | 1992 |
Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Card | 1992 |
Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiomegaly; Cilazapril; Coronary Cir | 1991 |
Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blotting, Northern; Cardiomegaly; Enala | 1990 |
Regression of ventricular hypertrophy abolishes cardiocyte vulnerability to acute hypoxia.
Topics: Animals; Blood Gas Analysis; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Heart; Hemodynami | 1990 |
Effect on atrial natriuretic peptides of chronic treatment with alpha-methyldopa and hydralazine in spontaneously hypertensive rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Heart Atria; Heart Ventricles; Hyd | 1990 |
Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure.
Topics: Adult; Animals; Cardiac Output, Low; Cardiomegaly; Coronary Circulation; Coronary Disease; Coronary | 1990 |
Left ventricular hypertrophy in hypertensive patients.
Topics: Cardiomegaly; Drug Therapy, Combination; Humans; Hydralazine; Hypertension; Prazosin | 1989 |
Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats.
Topics: Animals; Arteries; Blood Pressure; Blood Volume; Cardiomegaly; Heart Rate; Heart Ventricles; Hydrala | 1989 |
Structural change in the rat hindlimb during deoxycorticosterone acetate hypertension; its reversibility and prevention.
Topics: Animals; Arterioles; Cardiomegaly; Desoxycorticosterone; Hindlimb; Hydralazine; Hypertension; Male; | 1989 |
Antitrophic properties of antihypertensive drugs may depend solely on their blood pressure-lowering capability. A comparative study of isradipine, hydralazine, and metoprolol.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Coronary V | 1989 |
Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats.
Topics: Animals; Cardiac Volume; Cardiomegaly; Coronary Circulation; Coronary Vessels; Hydralazine; Hyperten | 1989 |
Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy.
Topics: Animals; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Coronary Circulation; Heart; Hydralaz | 1989 |
Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Collagen; Hemodynamics; Hydralazine; Hypertension; Myocardium | 1989 |
Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade.
Topics: Animals; Captopril; Cardiomegaly; Heart; Hydralazine; Isoenzymes; Male; Myosins; Propranolol; Rats; | 1989 |
Fatty acid binding protein of cardiac muscle in spontaneously hypertensive rats: effect of hypertrophy and its regression.
Topics: Animals; Blood Pressure; Cardiomegaly; Carrier Proteins; Enalapril; Fatty Acid-Binding Protein 7; Fa | 1988 |
Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats.
Topics: Animals; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; Epinephrine; Heart; Heart Rate; He | 1988 |
Myocardial hypertrophy in rats with renal insufficiency.
Topics: Adenosine Triphosphatases; Animals; Blood Pressure; Blood Transfusion; Calcium; Cardiomegaly; Hydral | 1985 |
Effects of hydralazine on blood pressure, pressor mechanisms, and cardiac hypertrophy in two-kidney, one-clip hypertensive rats.
Topics: Animals; Blood Pressure; Blood Volume; Cardiomegaly; Drug Tolerance; Hydralazine; Hypertension, Reno | 1986 |
Effects of vasodilators on the coronary circulation in congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiomegaly; Cilazapri | 1988 |
Coronary vascular function and morphology in hydralazine treated DOCA salt rats.
Topics: Animals; Cardiomegaly; Coronary Vessels; Desoxycorticosterone; Hydralazine; Hypertension; Rats; Rats | 1988 |
Influence of hydralazine consumption on allylamine induced myocardial fibrosis and hypertrophy in rats.
Topics: Allyl Compounds; Amines; Animals; Aorta, Thoracic; Cardiomegaly; Coronary Vessels; Diet; Endomyocard | 1974 |
Aspects of the relation between functional and structural cardiovascular factors in primary hypertension. Experimental studies in spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Capillary Resistance; Cardiac Output; Cardiomegaly; Coronary Circula | 1974 |
Cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Age Factors; Angiotensin II; Animals; Cardiomegaly; DNA; Heart Ventricles; Hydralazine; Hypertension | 1974 |
Characteristics of hypertension in the black population.
Topics: Adult; Angiotensin II; Animals; Black or African American; Cardiomegaly; Cerebrovascular Disorders; | 1974 |